Discover the full management transaction log of Selectis Health, INC., a listed equity based in United States. Shares are listed on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Selectis Health, INC. has logged 12 public disclosures. Market capitalisation: €10.9m. The latest transaction was filed on 13 January 2022 — C. Among the most active insiders: Baller Lance. All data is openly available.
0 of 0 declarations
Selectis Health, Inc. (ticker: GBCS) is a U.S.-based healthcare company whose shares are quoted on the OTCQB market, a structure that often places it in the same screening universe as small-cap U.S. equities that investors monitor alongside NYSE/NASDAQ names. The company is incorporated in the United States and operates from Greenwood Village, Colorado. Its corporate history traces back to Global Healthcare REIT, Inc., and the rebrand to Selectis Health was intended to better match the business model, which is now centered on owning and operating healthcare facilities rather than functioning as a traditional REIT-style shell. ([sec.gov](https://www.sec.gov/Archives/edgar/data/727346/000149315226016827/0001493152-26-016827-index-headers.html?utm_source=openai)) From an industry standpoint, Selectis Health is positioned as a niche operator in long-term and post-acute care. Its business includes ownership and/or operation of healthcare facilities serving seniors and recovering patients, with services spanning skilled nursing, rehabilitation, assisted living, speech therapy, occupational therapy, physical therapy, social services, and broader healthcare support functions. This makes the company a highly specialized participant in a structurally attractive but operationally demanding segment of the U.S. healthcare market. Demand is supported by demographic aging, but the sector also carries meaningful exposure to labor costs, staffing availability, reimbursement pressure, and state/federal regulatory complexity. ([sec.gov](https://www.sec.gov/Archives/edgar/data/727346/000149315223043689/ex99-1.htm?utm_source=openai)) Geographically, Selectis has historically described operations in Arkansas, Georgia, Ohio, and Oklahoma, and management has referenced a growth strategy focused on expanding its footprint in the American South-Central and Southeastern markets. That geographic positioning is important for investors because it suggests a regionally concentrated platform rather than a national scale operator. In competitive terms, Selectis competes in a fragmented market populated by regional operators, private owners, and larger public peers. Its competitive edge is less about scale and more about local operating expertise, asset-level management, and the ability to improve or reposition facilities through active portfolio management. ([sec.gov](https://www.sec.gov/Archives/edgar/data/727346/000149315223043689/ex99-1.htm?utm_source=openai)) Recent corporate developments have been eventful. In 2024, Selectis announced Adam Desmond as permanent Chief Executive Officer, signaling leadership stabilization. In 2025, the company’s stock was upgraded to OTCQB, which typically enhances market visibility and trading quality relative to lower OTC tiers. The company also continued to reshape its portfolio, including the sale of certain Georgia facilities, indicating a disciplined asset rationalization approach. More recently, in March 2026, Black Pearl Equities launched a tender offer to acquire up to 100% of Selectis Health at $5.05 per share in cash, an important strategic event for shareholders that underscores how corporate actions may matter more than conventional operating momentum in this name. For investors, Selectis Health remains a small-cap U.S. healthcare operator on the OTC market with a distinctly event-driven profile. ([nasdaq.com](https://www.nasdaq.com/press-release/selectis-health-makes-key-leadership-announcement-2024-10-17?utm_source=openai))